Sintilimab (Tyvyt®/达伯舒®) 信迪利单抗 Research code: IBI-308 简介 信迪利单抗(IBI-308)是信达生物开发的一种全人源单克隆抗体,靶向于程序性死亡受体1(PD-1),通过阻断 体内PD-1与配体PD-L1之间的结合,使T细胞发挥正常作用,进而利用自身免疫清除肿瘤细胞。信迪利单抗用于 至少经过二线系统化疗的复发或...
Sintilimab, marketed as TYVYT®(sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, bl...
Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of ELUNATE®(fruquintinib) and TYVYT®(sintilimab injection) has been
Innovent Biologics, a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody at CIIE 2019. The medicine works...
SUZHOU, China, Aug. 6, 2019 /PRNewswire/ -- Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer
Eli Lilly and Company (Lilly) and Innovent Biologics have agreed to expand their alliance for the blood cancer drug TYVYT (sintilimab injection) beyond China in a deal worth up to $1bn. Lilly acquires global licensing rights to cancer drug TYVYT from Innovent. (Credit: Momoneymoproblemz/Wik...